NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

330.60 -5.80 (-1.72%)

4.0M NSE+BSE Volume

NSE 05 Jun, 2025 3:56 PM (IST)

39,691.8

Market Cap

Market Leader

1.2

Beta 1Year

Very High Volatility

Regulatory Approval

Biocon receives CDSCO nod for Liraglutide, used to treat Type 2 diabetes in adults and children See details

Biocon Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Biocon Ltd. from all sources in a single place.

Load latest

Is Biocon Ltd. worth buying?

716 Votes:

Buy 75.14%

Sell 16.34%

Hold 8.52%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >